Previous 10 | Next 10 |
In the months since I took profits on Innoviva Inc. ( INVA ), the shares are down about 9.25% against a loss of 6% for the overall market. I thought I’d look in on the name again to see if I should continue to avoid or not. I’ll try to make this determination based on the finan...
WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the closing of the second tranc...
Investing in leading growth stocks can be great, and investing in leading growth stocks with attractive profitability can be even better. The following paragraphs are introducing a quantitative screener focused on companies with superior growth rates in revenue and strong profitability metrics...
Pavel Raifeld to continue the implementation of the Company’s strategy and focus on value creation for shareholders Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”) today announced the appointment of Pavel Raifeld as Chief Executive Officer effective May 20, 2020. Mr. ...
WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2020 financial results and provided a bu...
Innoviva (NASDAQ: INVA ): Q1 GAAP EPS of $0.59 beats by $0.30 . More news on: Innoviva, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Total net revenue increased by 43% to $78.7 million in the first quarter of 2020, compared to the same quarter in 2019. Income before income taxes increased by 96% to $94.9 million in the first quarter of 2020, compared to the same quarter in 2019. Innoviva, Inc. (NASDAQ:INVA) ("...
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that it has completed the init...
The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) announced today that, due to the public health impact of the coronavirus pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual me...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...